Gianluigi Ardissino1, Antenore Giussani2, Valentina Capone3, Sara Testa3, Cristiano Gandini4, Giovanni Montini3. 1. Center for HUS Prevention Control and Management at the Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 9, 20122, Milano, Italy. ardissino@centroseu.org. 2. Kidney Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy. 3. Center for HUS Prevention Control and Management at the Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 9, 20122, Milano, Italy. 4. Pediatric Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Abstract
BACKGROUND: Fenoldopam, a vasodilating agent, may represent a potential therapeutic opportunity to increase renal perfusion in those conditions where renal hemodynamics are severely impaired by vascular sub-occlusion, as, indeed, is the case in thrombotic microangiopathies. METHODS: The renal resistance index (RRI) was measured, on and off fenoldopam, in 27 children with STEC-HUS. RESULTS: A 12% decrease in RRI was observed on fenoldopam compared to off treatment without changes in the systemic hemodynamics and with no side effects. CONCLUSIONS: If confirmed in larger series, fenoldopam may become an important addition to supportive care to reduce ischemic damage in STEC-HUS and improve long-term outcomes.
BACKGROUND: Fenoldopam, a vasodilating agent, may represent a potential therapeutic opportunity to increase renal perfusion in those conditions where renal hemodynamics are severely impaired by vascular sub-occlusion, as, indeed, is the case in thrombotic microangiopathies. METHODS: The renal resistance index (RRI) was measured, on and off fenoldopam, in 27 children with STEC-HUS. RESULTS: A 12% decrease in RRI was observed on fenoldopam compared to off treatment without changes in the systemic hemodynamics and with no side effects. CONCLUSIONS: If confirmed in larger series, fenoldopam may become an important addition to supportive care to reduce ischemic damage in STEC-HUS and improve long-term outcomes.
Authors: Gianluigi Ardissino; Silvia Ghiglia; Patrizia Salice; Michela Perrone; Sandra Piantanida; Francesco L De Luca; Silvia Di Michele; Lucia Filippucci; Elena R A Dardi; Tiziana Bollani; Antonella Mezzopane; Bertrand Tchane; Sebastiano A G Lava Journal: Pediatr Nephrol Date: 2020-01-03 Impact factor: 3.714
Authors: R R Weber; C E McCoy; J A Ziemniak; E D Frederickson; L I Goldberg; M B Murphy Journal: Br J Clin Pharmacol Date: 1988-01 Impact factor: 4.335
Authors: Gregory B Hammer; Susan T Verghese; David R Drover; Myron Yaster; Joseph R Tobin Journal: BMC Anesthesiol Date: 2008-10-06 Impact factor: 2.217